Leucine, a B2B SaaS startup, has raised $7 million to develop its AI capabilities and widen its outreach to additional facilities and customers. Leucine claims its platform can be implemented in just eight weeks.
Through its Compliance Cloud platform, Leucine offers real-time performance monitoring, compliance management, and actionable insights, utilising AI to digitise workflows and offer proactive compliance insights.
“This latest funding round will enable Leucine to bring the power of LLMs (large language models) and associated technologies to make significant advances in pharma manufacturing,” said Rohit Jain, Co-founder and Partner at Pravega Ventures.
Leucine AI tool posses rapid depolyment capabilities
The firm’s proprietary AI-enabled digital process builder rapidly converts paper-based SOPs into digital formats, which in turn reduces the digitisation cycle, from 6-8 months down to 3-5 days, says the company.
“Our models are trained on a wealth of pharma data, which allows the platform to create custom workflows enriched with GxP compliance measures, enabling us to deliver unparalleled value at breakneck speed,” Vivek Gera, CEO & Co Founder of Leucine, said.
GxP (good practice) refers to a set of quality standards and regulations established to guarantee the safety, effectiveness, and quality of bio/pharmaceutical products throughout their entire lifecycle, including manufacturing, control, storage, and distribution, while ensuring they meet their intended purposes.
The firm is currently deployed at over 30 companies across more than 300 pharmaceutical manufacturing facilities in 10 countries. Over the past year, the company says, it has experienced significant growth, with a 2X increase in the number of facilities using their product.
The new AI capability, Leucine 10x, aims to change how decisions are made in pharmaceutical manufacturing by providing AI co-pilots that digitise paper-based processes, create a digital twin of the shop floor, collaborate on production plans, and speed up root cause analysis of deviations in the manufacturing process.
“We’re excited to share that Leucine10x is already operational in select customer facilities under a trusted tester agreement. The response has been incredibly positive, and due to high demand, we’re currently enrolling new customers through a waitlist,” Mustaq Singh Bijral, Co-founder and CPO of Leucine, said.
Founded in 2019, the firm aims to modernise compliance processes, minimise compliance failures, reduce costs, and enhance productivity in the pharma sector with its AI-powered digital platform. The company has gained traction with around 35 pharma companies across 10 countries.
The Series A funding round was led by Ecolab Inc, with participation from Pravega Ventures, Axilor Ventures, Techstars, and angel investors. New York-based Leucine uses AI to digitise and streamline pharmaceutical manufacturing, replacing paper records with digital processes.
